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Since the first reports of ablation therapy being used to treat
atrial fibrillation, the field has exploded with studies, new
techniques, and new technologies (1). It is no wonder that
such fervor is associated with this topic. Our medical
options to maintain sinus rhythm have been generally poorly
effective, riddled with side effects, and in some cases
associated with increased mortality (2,3). Even in the
AFFIRM (Atrial Fibrillation Follow-up Investigation of
Rhythm Management) trial, the largest study of atrial
fibrillation to date, patients did better in sinus rhythm, but
the medical therapy was poorly effective and possibly detri-
mental. This study is often cited as showing that rate control
and rhythm control are equivalent, but the investigators’
own conclusion suggest otherwise by stating, “If an effective
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method for maintaining sinus rhythm with fewer adverse
effects were available, it might be beneficial” (4). Patients are
also actively seeking alternatives to antiarrhythmic drug
therapy. Although the symptomatic spectrum of atrial
fibrillation is broad, patients with symptoms frequently do
not accept ineffective medications or side effects, and many
physicians find patients requesting ablation therapy. This is
somewhat unique for electrophysiologists. In the case of
implantable devices, patients are seen in the hospital or
referred from cardiologists. Many of these patients have no
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procedure. The atrial fibrillation patients, however, may
research the Internet and come armed with recently pub-
lished studies in hand.
Ablation for paroxysmal atrial fibrillation in patients with
no structural heart disease appears to have excellent success
rates in excess of 80% (5,6). Some preliminary studies
suggest that ablation may become a first-line treatment in
such patients (7). These studies have shown improved
success and reduced symptoms and hospitalization com-
pared to standard antiarrhythmic therapy, with low compli-
cation rates (8). Achieving such high success rates in
long-standing persistent atrial fibrillation has been more
challenging. Isolation of the pulmonary veins alone may not
be sufficient to achieve optimal success. Adjunctive strate-
gies have included ablation of fractionated electrograms,
linear lesions, and isolation of the left atrial appendage
(9–11). So far, no consensus exists to the best strategy.
Long-standing persistent atrial fibrillation is one of our
most difficult challenges. Certainly, medical therapy to
maintain sinus rhythm does not appear to be a better option
for this group (12,13). We should certainly see this as a
more advanced disease. It is more frequently associated with
structural heart disease and likely represents a more diseased
substrate. This is analogous to metastatic cancer for the
oncologist. It is more difficult to treat, with lower success
rates, and is much more challenging than localized, more
benign disease. When the electrophysiologist sees low
success rates, it tends to be viewed as failure when compared
to the high success of accessory pathway ablation; however,
the oncologist sees even modest success as a victory and
something on which to build further success.
The paper by Tilz et al. (14) in this issue of the Journal
discusses the 5-year outcomes of a sequential ablation
strategy in patients with long-standing persistent atrial
fibrillation. The study included 202 patients enrolled be-
tween 2003 and 2007. The median duration of persistent
atrial fibrillation was 3 years. Sixteen percent of patients had
structural heart disease and 77% had hypertension. That
would certainly count as a challenging group of patients.
The ablation strategy is somewhat unique in that all
patients underwent isolation of the pulmonary veins and
then were cardioverted if they did not resume normal sinus
rhythm during the venous isolation, which most did not.
After a 30-min waiting period, if no further atrial fibrillation
was seen spontaneously, the procedure was terminated, and
the patients were considered responders to venous isolation.
If atrial fibrillation was again seen, the trigger was ablated.
If cardioversion was unsuccessful, fractionated electrograms
were ablated, and linear lesions were performed if macro-
reentrant atrial tachycardia was seen. A similar strategy was
performed in repeat procedures. This algorithm is some-
what unique compared to other methods of ablating long-
standing persistent atrial fibrillation. It appears to be a more
conservative strategy compared to ablating until atrial fibril-
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others have reported, most patients with long-standing
persistent atrial fibrillation do not organize with venous
isolation alone, and ablation outside the veins is performed
in the majority of patients (15). In this population, 165
patients underwent pulmonary vein isolation alone as the
first procedure. If one assumes that extravenous ablation is
required for long-standing persistent afibrillation patients,
then this would tend to skew the population to more
procedures. The patients were enrolled over a long period,
and some of the newer techniques would not have been fully
elucidated during the enrollment period, which could also
influence the need for repeat procedures and possibly
success.
Overall, the success rates are not that dissimilar when
compared to those of other reports (15–17). After the last
procedure, 45% were in sinus rhythm after a median of 50
months of follow-up. Atrial fibrillation was improved in
another 23% of patients by maintaining sinus rhythm on
antiarrhythmic medications or becoming paroxysmal. This
makes at least two-thirds of the population improved after
a long follow-up. This is not an inconsequential number,
and would be seen as a major victory in cancer medicine.
The complication rates do not appear out of line.
Other than the minimal extravenous ablation, other
potential limitations include the relatively high incidence of
venous reconnection found at follow-up procedures and
somewhat limited monitoring. The study reports that after
the first procedure, 77% of first-time redo procedures had
reconnection and about a quarter of second redo procedures
had reconnection. Considering that isolation is the basis of
the procedure, persistent isolation may reduce the need for
repeat procedures. Also, intermittent 24-h Holter monitor-
ing may underestimate the recurrence, but in this popula-
tion, not being in persistent atrial fibrillation is a success.
Long-standing persistent atrial fibrillation has similarities
to metastatic cancer. It is 1 of our most difficult cases to
treat. In the past, patients who were symptomatic were told
that no other options existed and were expected to learn to
live with their burden. Ablation therapy has provided an
option that can benefit even the majority of patients. On the
basis of this study, most patients were improved. Electro-
physiologists tend to be disappointed by these types of
numbers, but in perspective, this is not a failure. In cancer
medicine, this would be considered a raging success. Addi-
tionally, some aspects of this study suggest that we can do
even better. The largest limitation to these procedures is the
lack of durability of venous electrical isolation. The majority
of patients had recovered venous conduction at the first redo
procedure. That is not unexpected, considering that we
continue to perform large-area ablation lesions with cathe-
ters designed for single-point ablation. Technology may
allow us to perform these lesions more efficiently and with a
higher likelihood of permanent isolation. That would cer-
tainly decrease the number of redo procedures and poten-
tially increase the initial and possibly overall success rate.Also, perhaps cardioversion after venous isolation is not the
best method to achieve optimal success. Ablation of frac-
tionated electrograms or left atrial appendage isolation may
increase the overall success rate. It appears we do have a path
to achieve reasonable success rates in this population.
Much remains unanswered in the ablation treatment of
long-standing persistent afibrillation. How much should we
ablate? Does ablation alter stroke risk? Are the risks and
benefits of anticoagulation therapy different after a success-
ful ablation procedure? Payers may seek to limit ablation for
such patients because the limited success, but is this argu-
ment justified when compared to other medical conditions
such as surgical treatment of back pain or chemotherapy for
metastatic cancer? A therapy that benefits the majority of
patients should be perceived positively, and efforts to im-
prove the outcomes should continue.
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